Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Cinrebafusp alfa |
Trade Name | |
Synonyms | PRS-343|PRS 343|PRS343 |
Drug Descriptions |
Cinrebafusp alfa is a bispecific antibody that targets both TNFRSF9 (CD137; 4-1BB) and ERBB2 (HER2), potentially resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (PMID: 31138587, PMID: 39235868). |
DrugClasses | HER2 (ERBB2) Antibody 77 TNFRSF9 Antibody 32 |
CAS Registry Number | 2218515-90-1 |
NCIT ID | C142890 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Cinrebafusp alfa | Atezolizumab Cinrebafusp alfa | 0 | 1 |
Cinrebafusp alfa | Cinrebafusp alfa | 0 | 1 |
Cinrebafusp alfa + Paclitaxel + Ramucirumab | Cinrebafusp alfa Paclitaxel Ramucirumab | 0 | 1 |
Cinrebafusp alfa + Tucatinib | Cinrebafusp alfa Tucatinib | 0 | 1 |